Tuesday, October 23, 2018
- 9:00AM-11:00AM
-
Abstract Number: 2444
The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with/without Prior Cancers
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2068
The Role of Extracellular Matrix Metalloproteinase Inducer Emmprin in the Pathogenesis of Psoriatic Arthritis
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 2380
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis- 9:00AM-11:00AM
-
Abstract Number: 2403
The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study
Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis- 9:00AM-11:00AM
-
Abstract Number: 2620
The Treatment Choices and Response for a Psoriatic Arthritis Inception Cohort
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment- 9:00AM-11:00AM
-
Abstract Number: 2165
The Trend of Utilization of Therapeutic Plasmapheresis Among Select Rheumatologic Diseases
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 2482
The Use of Any Conventional Synthetic DMARD Is Associated with Better Indexes of the Physical Component Evaluated By 12-Item Short-Form Health Survey : Analysis of a Cohort of RA Patients
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2279
Therapeutic Value of Canakinumab in Patients with Yao Syndrome
Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease- 9:00AM-11:00AM
-
Abstract Number: 2765
Thyroid Artery Involvement Detected By Colour-Doppler Ultrasonography in an Incipient, Single Centre Giant Cell Arteritis Cohort
Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica- 9:00AM-11:00AM
-
Abstract Number: 2625
TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment- 9:00AM-11:00AM
-
Abstract Number: 2327
To Screen or Not to Screen?Dexa Ordering Patterns in SLE Patients Who Take Systemic Glucocorticoids
Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster- 9:00AM-11:00AM
-
Abstract Number: 2752
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica- 9:00AM-11:00AM
-
Abstract Number: 2758
Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study
Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica- 9:00AM-11:00AM
-
Abstract Number: 2746
Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study